

Appl. No. 09/775,046
Amdt. Dated April 1, 2004
Reply to Office Action of October 14, 2003

IN THE CLAIMS:

Claims 1-3 (withdrawn)

Claims 4-11 (cancelled)

Claims 12-20 (withdrawn)

Claim 21 (new): A method of modulating cutaneous inflammation comprising contacting a cell expressing IL-1R6 with an exogenous antagonist of mammalian IL-1 ϵ (SEQ ID NO: 4 or 10) wherein the antagonist is:

- a) an antibody or antigen binding fragment thereof that specifically binds to IL-1 ϵ or IL-1R6 (SEQ ID NO: 13 or 15); or
- b) IL-1 δ (SEQ ID NO: 2 or 11).

Claim 22 (new): The method of Claim 21, wherein cutaneous inflammation is inhibited by the antagonist of IL-1 ϵ .

Claim 23 (new): The method of Claim 21, wherein the antibody or antigen binding fragment thereof neutralizes IL-1 ϵ or IL-1R6.

Claim 24 (new): The method of Claim 21, wherein the cutaneous inflammation is psoriasis.

Claim 25 (new): The method of Claim 24, wherein the psoriasis is lesional psoriasis.

Appl. No. 09/775,046
Amdt. Dated April 1, 2004
Reply to Office Action of October 14, 2003

Claim 26 (new): The method of Claim 21, wherein the cell expressing IL-1R6 is selected from the group consisting of:

- a) a keratinocyte;
- b) an epithelial cell;
- c) a fibroblast cell; or
- d) a monocyte cell.